X-Ray Crystal Structures of an Orally Available Aminopeptidase Inhibitor, Tosedostat, Bound to Anti-Malarial Drug Targets Pfa-M1 and Pfa-M17

ABSTRACTNew anti‐malarial treatments are desperately required to face the spread of drug resistant parasites. Inhibition of metalloaminopeptidases, PfA‐M1 and PfA‐M17, is a validated therapeutic strategy for treatment of Plasmodium falciparum malaria. Here, we describe the crystal structures of PfA‐M1 and PfA‐M17 bound to chemotherapeutic agent Tosedostat. The inhibitor occupies the enzymes' putative product egress channels in addition to the substrate binding pockets; however, adopts different binding poses when bound to PfA‐M1 and PfA‐M17. These findings will be valuable for the continued development of selective inhibitors of PfA‐M1 and PfA‐M17. Proteins 2015; 83:789–795. © 2015 Wiley Periodicals, Inc.